Detail akcie BB Biotech AG online

Business Summary: BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, BB BIOTECH AG revenues increased from SF530K to SF112.2M. Net income totaled SF75.9M vs. loss of SF206.6M. Revenues reflect Foreign exchange gains net increase of 22% to SF599K, Interest Income increase from SF35K to SF84K, Other income increase of 20% to SF6K. Net Income reflects Management fees decrease of 10% to SF24.9M (expense), Other Expenses decrease of 13% to SF3.9M (expense).